The drospirenone (DRSP)-only pill: clinical implications in the daily use

Literature

• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1-2):171–180.
   PubMed Web of Science ®Google Scholar
• Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11(1):41–47.
   PubMedGoogle Scholar
• Trussel J, Card J, Hogue C. Adolescent sexual behavior, pregnancy, and childbearing. In: Hatcher R, editor. Contraceptive technology. 17th rev. edn. New York: Irvington Publishers; 1998.
   Google Scholar
• Bearak J, Popinchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152–e1161.
   PubMed Web of Science ®Google Scholar
• Institute of medicine committee on unintended pregnancies. In: Brown SS, Eisenberg L, editors. The best intentions: unintended pregnancy and the Well-Being of children and families. Washington (DC): National Academies Press (US); 1995.
   Google Scholar
• PRAC referral assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. Combined hormonal contraceptives containing medicinal products INN: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate; 2013. Procedure number: EMEA/H/A-31/1356.
   Google Scholar
• Kuhl H. Pharmacology of progestogens. J Reproduktionsmed Endokrinol. 2011;8(Sonderheft 1):157–177.
   Google Scholar
• Creinin MD, Jensen JT. Oral contraceptive generations – time to stop using a marketing myth to define nomenclature. Contraception. 2020;102(3):143–144.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone. Oncotarget. 2017;8(47):83334–83342.
   PubMedGoogle Scholar
• Jordan WM, Anand JK. Pulmonary embolism. Lancet. 1961;278(7212):1146–1147.
   Google Scholar
• Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347:f5298.
   PubMed Web of Science ®Google Scholar
• Thorogood M, Villard-Mackintosh L. Combined oral contraceptives: risks and benefits. Br Med Bull. 1993;49(1):124–139.
   PubMed Web of Science ®Google Scholar
• Wharton C, Blackburn R. Lower dose pills. Population Rep. 1988;16:1–31.
   Google Scholar
• Stolley PD, Tonascia JA, Tockman MS, et al. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol. 1975;102(3):197–208.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001–9. BMJ. 2011; 25343:d6423.
   PubMed Web of Science ®Google Scholar
• Schindler AE. Differential effects of progestins on hemostasis. Maturitas. 2003;46:31–37.
   PubMed Web of Science ®Google Scholar
• Fotherby K. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception. 1996;54(2):59–69.
   PubMed Web of Science ®Google Scholar
• Winkler UH. Hormone replacement therapy and hemostasis: principles of a complex interaction. Maturitas. 1996;24(3):131–145.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32(9):749–751.
   PubMed Web of Science ®Google Scholar
• Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92(5):439–444. contraception.2015.07.014 Epub 2015 July 29.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone only pill. Acta Obstet Gynecol Scand. 2019;98(12):1549–1557.
   PubMed Web of Science ®Google Scholar
• Kimble T, Burke AE, Barnhart KT, et al. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen. Contracept X. 2020;2:100020.
   PubMedGoogle Scholar
• Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC Womens Health. 2020;20(1):218.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestin, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816–1821.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003;67(6):423–429.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Napolitano A, et al. Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study. Contraception. 2013;88(3):413–417.
   PubMed Web of Science ®Google Scholar
• Pomp ER, Le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007;139(2):289–296. 06780.x
   PubMed Web of Science ®Google Scholar
• Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83(2):97–102.
   PubMed Web of Science ®Google Scholar
• Jick SS, Hernandez RK, Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011;342:d2151.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Palacios S, Colli E. Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg. Gynecol Endocrinol. 2022;38(4):333–338.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Palacios S. Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel. Gynecol Endocrinol. 2021;37(12):1121–1127.
   Google Scholar
• Vogel B, Acevedo M, Appelman Y, et al. Jacqueline saw, liesl zühlke, roxana mehran. The lancet women and cardiovascular disease commission: reducing the global burden by 2030. The Lancet Commission. 2021;397(10292):2385–2438.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Shaw KM, Kuklina EV, et al. Hypertension in women of reproductive age in the United States: NHANES 1999–2008. PLoS One. 2012;7(4):e36171.
   PubMed Web of Science ®Google Scholar
• Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences: the tromso study, 1986–1995. Arch Intern Med. 2000;160(18):2847–2853.
   PubMedGoogle Scholar
• Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016;118(11):1723–1735.
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the framingham experience. Arch Intern Med. 2002;162(16):1867–1872.
   PubMedGoogle Scholar
• Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378(9799):1297–1305.
   PubMed Web of Science ®Google Scholar
• Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the global burden of disease study 2015. Lancet. 2017;389(10082):1885–1906.
   PubMed Web of Science ®Google Scholar
• Curtis KM, Mohllajee AP, Martins SL, et al. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006;73(2):179–188.
   PubMed Web of Science ®Google Scholar
• Practice Guideline. ACOG practice bulletin no. 206: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133:e128–50.
   Web of Science ®Google Scholar
• Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319(20):1313–1317.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E. Drospirenone 4 mg in a 24/4 regimen maintains inhibition of ovulation even after a 24-h delay pill intake – pharmacological aspects and comparison to other progestin-only pills. Eur Rev Med Pharmacol Sci. 2022;26:1994–1999.
   PubMed Web of Science ®Google Scholar
• Cerazette® Summary of product characteristics. 2020. https://www.medicines.org.uk/emc/product/1698/smpc#gref
   Google Scholar
• Exeltis. Slynd. 2019. www.drugs.com/pro/slynd.html
   Google Scholar
• Apter D, Colli E, Gemzell-Danielsson K, et al. Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase. Contraception. 2020;101(6):412–419.
   PubMed Web of Science ®Google Scholar